294 related articles for article (PubMed ID: 33168611)
1. Pharmacokinetics of Benznidazole in Experimental Chronic Chagas Disease Using the Swiss Mouse-Berenice-78 Trypanosoma cruzi Strain Model.
de Jesus SM; Pinto L; Moreira FL; Nardotto GHB; Cristofoletti R; Perin L; Fonseca KDS; Barbêdo P; Bandeira LC; Vieira PMA; Carneiro CM
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168611
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics and biodistribution of benznidazole in mice.
Perin L; Pinto L; Balthazar Nardotto GH; da Silva Fonseca K; Oliveira Paiva B; Fernanda Rodrigues Bastos Mendes T; Molina I; Correa-Oliveira R; Melo de Abreu Vieira P; Martins Carneiro C
J Antimicrob Chemother; 2020 Aug; 75(8):2213-2221. PubMed ID: 32356873
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of Benznidazole in Healthy Volunteers and Implications in Future Clinical Trials.
Molina I; Salvador F; Sánchez-Montalvá A; Artaza MA; Moreno R; Perin L; Esquisabel A; Pinto L; Pedraz JL
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167552
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Tissue Distribution of Benznidazole after Oral Administration in Mice.
Perin L; Moreira da Silva R; Fonseca KD; Cardoso JM; Mathias FA; Reis LE; Molina I; Correa-Oliveira R; Vieira PM; Carneiro CM
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167558
[TBL] [Abstract][Full Text] [Related]
5. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
[TBL] [Abstract][Full Text] [Related]
6. Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains.
Veloso VM; Carneiro CM; Toledo MJ; Lana M; Chiari E; Tafuri WL; Bahia MT
Mem Inst Oswaldo Cruz; 2001 Oct; 96(7):1005-11. PubMed ID: 11685270
[TBL] [Abstract][Full Text] [Related]
7. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.
Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S;
J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of continuous versus intermittent administration of nanoformulated benznidazole during the chronic phase of Trypanosoma cruzi Nicaragua infection in mice.
Rial MS; Arrúa EC; Natale MA; Bua J; Esteva MI; Prado NG; Laucella SA; Salomon CJ; Fichera LE
J Antimicrob Chemother; 2020 Jul; 75(7):1906-1916. PubMed ID: 32274510
[TBL] [Abstract][Full Text] [Related]
9. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280
[TBL] [Abstract][Full Text] [Related]
10. An update on benznidazole for the treatment of patients with Chagas disease.
Thakare R; Dasgupta A; Chopra S
Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658
[TBL] [Abstract][Full Text] [Related]
11. Treatment with benznidazole in association with immunosuppressive drugs in mice chronically infected with Trypanosoma cruzi: investigation into the possible development of neoplasias.
Andrade SG; Mesquita IM; Jambeiro JF; Santos IF; Portella RS
Rev Soc Bras Med Trop; 2003; 36(4):441-7. PubMed ID: 12937719
[TBL] [Abstract][Full Text] [Related]
12. Chagas cardiomyopathy: The potential effect of benznidazole treatment on diastolic dysfunction and cardiac damage in dogs chronically infected with Trypanosoma cruzi.
Santos FM; Mazzeti AL; Caldas S; Gonçalves KR; Lima WG; Torres RM; Bahia MT
Acta Trop; 2016 Sep; 161():44-54. PubMed ID: 27215760
[TBL] [Abstract][Full Text] [Related]
13. Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease.
Vallejo A; Monge-Maillo B; Gutiérrez C; Norman FF; López-Vélez R; Pérez-Molina JA
Acta Trop; 2016 Dec; 164():117-124. PubMed ID: 27619190
[TBL] [Abstract][Full Text] [Related]
14. Response to chemotherapy with benznidazole of clones isolated from the 21SF strain of Trypanosoma cruzi (biodeme Type II, Trypanosoma cruzi II).
Campos RF; Guerreiro ML; Sobral Kde S; Lima Rde C; Andrade SG
Rev Soc Bras Med Trop; 2005; 38(2):142-6. PubMed ID: 15821788
[TBL] [Abstract][Full Text] [Related]
15. Assessing the Effectiveness of Curative Benznidazole Treatment in Preventing Chronic Cardiac Pathology in Experimental Models of Chagas Disease.
Francisco AF; Jayawardhana S; Taylor MC; Lewis MD; Kelly JM
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30082291
[TBL] [Abstract][Full Text] [Related]
16. Preclinical monitoring of drug association in experimental chemotherapy of Chagas' disease by a new HPLC-UV method.
Moreira da Silva R; Oliveira LT; Silva Barcellos NM; de Souza J; de Lana M
Antimicrob Agents Chemother; 2012 Jun; 56(6):3344-8. PubMed ID: 22450981
[TBL] [Abstract][Full Text] [Related]
17. Low-dose of benznidazole promotes therapeutic cure in experimental chronic Chagas' disease with absence of parasitism in blood, heart and colon.
Perin L; Fonseca KDS; de Carvalho TV; Carvalho LM; Madeira JV; Medeiros LDF; Molina I; Correa-Oliveira R; Carneiro CM; Vieira PMA
Exp Parasitol; 2020 Mar; 210():107834. PubMed ID: 31978394
[TBL] [Abstract][Full Text] [Related]
18. Benznidazole prevents endothelial damage in an experimental model of Chagas disease.
Molina-Berríos A; Campos-Estrada C; Lapier M; Duaso J; Kemmerling U; Galanti N; Leiva M; Ferreira J; López-Muñoz R; Maya JD
Acta Trop; 2013 Jul; 127(1):6-13. PubMed ID: 23529066
[TBL] [Abstract][Full Text] [Related]
19. Parasitaemia and parasitic load are limited targets of the aetiological treatment to control the progression of cardiac fibrosis and chronic cardiomyopathy in Trypanosoma cruzi-infected dogs.
Caldas IS; Menezes APJ; Diniz LF; Nascimento ÁFDSD; Novaes RD; Caldas S; Bahia MT
Acta Trop; 2019 Jan; 189():30-38. PubMed ID: 30290285
[TBL] [Abstract][Full Text] [Related]
20. The immunomodulatory effects of the Enalapril in combination with Benznidazole during acute and chronic phases of the experimental infection with Trypanosoma cruzi.
Leite ALJ; Paula Costa G; Lopes LR; Reis Mota LWD; Vieira PMA; Talvani A
Acta Trop; 2017 Oct; 174():136-145. PubMed ID: 28720491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
